皮下GS-441524治疗雪貂全身性冠状病毒相关疾病7例(2021-2024)

IF 1.9 2区 农林科学 Q2 VETERINARY SCIENCES
E Camba Caride, M Ardiaca García, C Bonvehí Nadeu, A Basurco Pérez, M Capdevila Andrés, A Montesinos Barceló, C Juan-Sallés
{"title":"皮下GS-441524治疗雪貂全身性冠状病毒相关疾病7例(2021-2024)","authors":"E Camba Caride, M Ardiaca García, C Bonvehí Nadeu, A Basurco Pérez, M Capdevila Andrés, A Montesinos Barceló, C Juan-Sallés","doi":"10.1111/jsap.13906","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Ferret systemic coronavirus-associated disease is usually fatal in ferrets, and no specific treatments have been available to date. This disease shares similarities with feline infectious peritonitis, which has been successfully treated with antivirals in recent years. This report describes the effects of GS-441524 in ferrets with naturally acquired ferret systemic coronavirus-associated disease.</p><p><strong>Materials and methods: </strong>Seven ferrets with ferret systemic coronavirus-associated disease confirmed by immunohistochemistry on biopsy samples were treated with subcutaneous GS-441524. Clinical signs and blood analysis including protein electrophoresis were periodically evaluated. Comorbidities and adverse effects during treatment were also recorded. Post-mortem examination with histopathological evaluation was conducted on the deceased ferrets.</p><p><strong>Results: </strong>Clinical signs included respiratory, gastrointestinal, ocular and neurological disturbances, weight loss, lethargy and organomegaly. Initial hypergammaglobulinaemia and low albumin-to-globulin ratio were present in all ferrets. The dose range was 2 to 15 mg/kg/sc SID, two or three times per week. Total treatment duration ranged from 24 to 103 weeks. The clinical condition of all ferrets rapidly improved with increasing body weight after treatment initiation. Haematocrit, albumin and thrombocyte count normalised during the course of antiviral therapy, and plasmatic gamma globulin concentrations returned to normal in six of the seven ferrets. Survival time from the initiation of therapy ranged from 36 to 175 weeks. Three ferrets died; no pyogranulomatous inflammatory lesions compatible with ferret systemic coronavirus-associated disease were noted, and immunohistochemistry for coronavirus antigens was negative in all three.</p><p><strong>Clinical significance: </strong>This study suggests injectable GS-441524 could be an effective treatment to improve the clinical status, haematological parameters and survival times of ferrets affected with ferret systemic coronavirus-associated disease.</p>","PeriodicalId":17062,"journal":{"name":"Journal of Small Animal Practice","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment with subcutaneous GS-441524 in ferrets affected by ferret systemic coronavirus-associated disease: seven cases (2021-2024).\",\"authors\":\"E Camba Caride, M Ardiaca García, C Bonvehí Nadeu, A Basurco Pérez, M Capdevila Andrés, A Montesinos Barceló, C Juan-Sallés\",\"doi\":\"10.1111/jsap.13906\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Ferret systemic coronavirus-associated disease is usually fatal in ferrets, and no specific treatments have been available to date. This disease shares similarities with feline infectious peritonitis, which has been successfully treated with antivirals in recent years. This report describes the effects of GS-441524 in ferrets with naturally acquired ferret systemic coronavirus-associated disease.</p><p><strong>Materials and methods: </strong>Seven ferrets with ferret systemic coronavirus-associated disease confirmed by immunohistochemistry on biopsy samples were treated with subcutaneous GS-441524. Clinical signs and blood analysis including protein electrophoresis were periodically evaluated. Comorbidities and adverse effects during treatment were also recorded. Post-mortem examination with histopathological evaluation was conducted on the deceased ferrets.</p><p><strong>Results: </strong>Clinical signs included respiratory, gastrointestinal, ocular and neurological disturbances, weight loss, lethargy and organomegaly. Initial hypergammaglobulinaemia and low albumin-to-globulin ratio were present in all ferrets. The dose range was 2 to 15 mg/kg/sc SID, two or three times per week. Total treatment duration ranged from 24 to 103 weeks. The clinical condition of all ferrets rapidly improved with increasing body weight after treatment initiation. Haematocrit, albumin and thrombocyte count normalised during the course of antiviral therapy, and plasmatic gamma globulin concentrations returned to normal in six of the seven ferrets. Survival time from the initiation of therapy ranged from 36 to 175 weeks. Three ferrets died; no pyogranulomatous inflammatory lesions compatible with ferret systemic coronavirus-associated disease were noted, and immunohistochemistry for coronavirus antigens was negative in all three.</p><p><strong>Clinical significance: </strong>This study suggests injectable GS-441524 could be an effective treatment to improve the clinical status, haematological parameters and survival times of ferrets affected with ferret systemic coronavirus-associated disease.</p>\",\"PeriodicalId\":17062,\"journal\":{\"name\":\"Journal of Small Animal Practice\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-06-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Small Animal Practice\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://doi.org/10.1111/jsap.13906\",\"RegionNum\":2,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"VETERINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Small Animal Practice","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1111/jsap.13906","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

摘要

目的:雪貂全身性冠状病毒相关疾病在雪貂中通常是致命的,迄今为止还没有特异性的治疗方法。这种疾病与猫传染性腹膜炎有相似之处,近年来已成功地用抗病毒药物治疗。本报告描述了GS-441524对患有自然获得性雪貂全身冠状病毒相关疾病的雪貂的影响。材料与方法:对7只活检标本经免疫组化证实为雪貂全身性冠状病毒相关疾病的雪貂进行皮下注射GS-441524。临床症状和血液分析包括蛋白质电泳定期评估。同时记录治疗期间的合并症和不良反应。对死亡的雪貂进行了尸检和组织病理学评估。结果:临床症状包括呼吸、胃肠、眼和神经系统紊乱、体重减轻、嗜睡和器官肿大。所有雪貂均存在初始高γ -球蛋白血症和低白蛋白-球蛋白比。剂量范围为2 ~ 15mg /kg/ scsid,每周2 ~ 3次。总治疗时间为24 ~ 103周。治疗开始后,所有雪貂的临床状况都随着体重的增加而迅速改善。在抗病毒治疗过程中,7只雪貂中的6只红细胞、白蛋白和血小板计数恢复正常,血浆丙种球蛋白浓度恢复正常。从治疗开始的生存时间从36到175周不等。三只雪貂死亡;没有发现与雪貂全体性冠状病毒相关疾病相一致的脓肉芽肿性炎症病变,并且三例患者的冠状病毒抗原免疫组化均为阴性。临床意义:本研究提示注射用GS-441524可有效改善雪貂全身性冠状病毒相关疾病患者的临床状态、血液学指标和生存时间。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Treatment with subcutaneous GS-441524 in ferrets affected by ferret systemic coronavirus-associated disease: seven cases (2021-2024).

Objectives: Ferret systemic coronavirus-associated disease is usually fatal in ferrets, and no specific treatments have been available to date. This disease shares similarities with feline infectious peritonitis, which has been successfully treated with antivirals in recent years. This report describes the effects of GS-441524 in ferrets with naturally acquired ferret systemic coronavirus-associated disease.

Materials and methods: Seven ferrets with ferret systemic coronavirus-associated disease confirmed by immunohistochemistry on biopsy samples were treated with subcutaneous GS-441524. Clinical signs and blood analysis including protein electrophoresis were periodically evaluated. Comorbidities and adverse effects during treatment were also recorded. Post-mortem examination with histopathological evaluation was conducted on the deceased ferrets.

Results: Clinical signs included respiratory, gastrointestinal, ocular and neurological disturbances, weight loss, lethargy and organomegaly. Initial hypergammaglobulinaemia and low albumin-to-globulin ratio were present in all ferrets. The dose range was 2 to 15 mg/kg/sc SID, two or three times per week. Total treatment duration ranged from 24 to 103 weeks. The clinical condition of all ferrets rapidly improved with increasing body weight after treatment initiation. Haematocrit, albumin and thrombocyte count normalised during the course of antiviral therapy, and plasmatic gamma globulin concentrations returned to normal in six of the seven ferrets. Survival time from the initiation of therapy ranged from 36 to 175 weeks. Three ferrets died; no pyogranulomatous inflammatory lesions compatible with ferret systemic coronavirus-associated disease were noted, and immunohistochemistry for coronavirus antigens was negative in all three.

Clinical significance: This study suggests injectable GS-441524 could be an effective treatment to improve the clinical status, haematological parameters and survival times of ferrets affected with ferret systemic coronavirus-associated disease.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Small Animal Practice
Journal of Small Animal Practice 农林科学-兽医学
CiteScore
3.30
自引率
6.20%
发文量
117
审稿时长
12-24 weeks
期刊介绍: Journal of Small Animal Practice (JSAP) is a monthly peer-reviewed publication integrating clinical research papers and case reports from international sources, covering all aspects of medicine and surgery relating to dogs, cats and other small animals. These papers facilitate the dissemination and implementation of new ideas and techniques relating to clinical veterinary practice, with the ultimate aim of promoting best practice. JSAP publishes high quality original articles, as well as other scientific and educational information. New developments are placed in perspective, encompassing new concepts and peer commentary. The target audience is veterinarians primarily engaged in the practise of small animal medicine and surgery. In addition to original articles, JSAP will publish invited editorials (relating to a manuscript in the same issue or a topic of current interest), review articles, which provide in-depth discussion of important clinical issues, and other scientific and educational information from around the world. The final decision on publication of a manuscript rests with the Editorial Board and ultimately with the Editor. All papers, regardless of type, represent the opinion of the authors and not necessarily that of the Editor, the Association or the Publisher. The Journal of Small Animal Practice is published on behalf of the British Small Animal Veterinary Association and is also the official scientific journal of the World Small Animal Veterinary Association
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信